Tumors of TPBC and ER+PR-HER2+ breast cancer were less frequently of a higher grade (grade 3 or undifferentiated, 48.9% and 58.6%, respectively) than those of ER-PR-HER2+ breast cancer (grade 3 or undifferentiated, 75.5%). This evidence concerns the gene ESR1 and breast cancer.